These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38339198)

  • 1. Bis(Disulfide)-Bridged Somatostatin-14 Analogs and Their [
    Tatsi A; Maina T; Waser B; Krenning EP; de Jong M; Reubi JC; Cordopatis P; Nock BA
    Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [DOTA]Somatostatin-14 analogs and their (111)In-radioligands: effects of decreasing ring-size on sst1-5 profile, stability and tumor targeting.
    Tatsi A; Maina T; Cescato R; Waser B; Krenning EP; de Jong M; Cordopatis P; Reubi JC; Nock BA
    Eur J Med Chem; 2014 Feb; 73():30-7. PubMed ID: 24378707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Agonist properties of putative small-molecule somatostatin sst2 receptor-selective antagonists.
    Nunn C; Langenegger D; Hurth K; Schmidt K; Fehlmann D; Hoyer D
    Eur J Pharmacol; 2003 Apr; 465(3):211-8. PubMed ID: 12681432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "To serve and protect": enzyme inhibitors as radiopeptide escorts promote tumor targeting.
    Nock BA; Maina T; Krenning EP; de Jong M
    J Nucl Med; 2014 Jan; 55(1):121-7. PubMed ID: 24287321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study.
    Tatsi A; Maina T; Cescato R; Waser B; Krenning EP; de Jong M; Cordopatis P; Reubi JC; Nock BA
    EJNMMI Res; 2012 Jun; 2(1):25. PubMed ID: 22682002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors.
    Ginj M; Zhang H; Waser B; Cescato R; Wild D; Wang X; Erchegyi J; Rivier J; Mäcke HR; Reubi JC
    Proc Natl Acad Sci U S A; 2006 Oct; 103(44):16436-41. PubMed ID: 17056720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications.
    Fani M; Braun F; Waser B; Beetschen K; Cescato R; Erchegyi J; Rivier JE; Weber WA; Maecke HR; Reubi JC
    J Nucl Med; 2012 Sep; 53(9):1481-9. PubMed ID: 22851637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [111In-DOTA]LTT-SS28, a first pansomatostatin radioligand for in vivo targeting of somatostatin receptor-positive tumors.
    Maina T; Cescato R; Waser B; Tatsi A; Kaloudi A; Krenning EP; de Jong M; Nock BA; Reubi JC
    J Med Chem; 2014 Aug; 57(15):6564-71. PubMed ID: 25007399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel sst(4)-selective somatostatin (SRIF) agonists. 1. Lead identification using a betide scan.
    Rivier J; Erchegyi J; Hoeger C; Miller C; Low W; Wenger S; Waser B; Schaer JC; Reubi JC
    J Med Chem; 2003 Dec; 46(26):5579-86. PubMed ID: 14667212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel sst(4)-selective somatostatin (SRIF) agonists. 3. Analogues amenable to radiolabeling.
    Erchegyi J; Waser B; Schaer JC; Cescato R; Brazeau JF; Rivier J; Reubi JC
    J Med Chem; 2003 Dec; 46(26):5597-605. PubMed ID: 14667214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent somatostatin undecapeptide agonists selective for somatostatin receptor 1 (sst1).
    Rivier JE; Hoeger C; Erchegyi J; Gulyas J; DeBoard R; Craig AG; Koerber SC; Wenger S; Waser B; Schaer JC; Reubi JC
    J Med Chem; 2001 Jun; 44(13):2238-46. PubMed ID: 11405660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
    Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
    J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of receptors for somatostatin in various tumors using different analogs.
    Srkalovic G; Cai RZ; Schally AV
    J Clin Endocrinol Metab; 1990 Mar; 70(3):661-9. PubMed ID: 1968467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel sst(4)-selective somatostatin (SRIF) agonists. 2. Analogues with beta-methyl-3-(2-naphthyl)alanine substitutions at position 8.
    Erchegyi J; Penke B; Simon L; Michaelson S; Wenger S; Waser B; Cescato R; Schaer JC; Reubi JC; Rivier J
    J Med Chem; 2003 Dec; 46(26):5587-96. PubMed ID: 14667213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting.
    Ginj M; Zhang H; Eisenwiener KP; Wild D; Schulz S; Rink H; Cescato R; Reubi JC; Maecke HR
    Clin Cancer Res; 2008 Apr; 14(7):2019-27. PubMed ID: 18381940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metal-ion-dependent biological properties of a chelator-derived somatostatin analogue for tumour targeting.
    Heppeler A; André JP; Buschmann I; Wang X; Reubi JC; Hennig M; Kaden TA; Maecke HR
    Chemistry; 2008; 14(10):3026-34. PubMed ID: 18246556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of different spacers on the biological profile of a DOTA-somatostatin analogue.
    Antunes P; Ginj M; Walter MA; Chen J; Reubi JC; Maecke HR
    Bioconjug Chem; 2007; 18(1):84-92. PubMed ID: 17226960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiolabeled bicyclic somatostatin-based analogs: a novel class of potential radiotracers for SPECT/PET of neuroendocrine tumors.
    Fani M; Mueller A; Tamma ML; Nicolas G; Rink HR; Cescato R; Reubi JC; Maecke HR
    J Nucl Med; 2010 Nov; 51(11):1771-9. PubMed ID: 20956465
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.